## **Claims**

- 1. Use of interleukin-18 for the manufacture of a medicament for the prevention, reduction and treatment of disorders of the skin associated with damage induced by UV-radiation.
- 2. Use according to claim 1, wherein the disorder is a disorder that can be alleviated and/or prevented by induction of the nucleotide excision repair (NER) pathway.
- 3. Use according to any of claims 1-2, wherein the disorder is selected from the group comprising sunburn, inflammation, skin aging and skin cancer.
- 4. Use according to any of the foregoing claims, wherein the disorder is associated with apoptosis.
- 5. Use according to any of the foregoing claims, wherein the UV-radiation covers at least a range of wavelengths from 220 nm to 350 nm.
- 6. Use according to any of the foregoing claims, wherein the UV-radiation covers at least a range of wavelengths from 250 nm to 330 nm.
- 7. Use according to any of the foregoing claims, wherein the UV-radiation covers at least a range of wavelengths from 290 nm to 320 nm.
- 8. Use according to any of claims 5-7, wherein the UV-radiation originates from natural and/or artificial sunlight.
- Use according to any of the foregoing claims comprising an application of said medicament to a patient in need thereof.
- 10. Use according to claim 9, wherein the application is systemic and/or topical.

- 11. Use according to any of claims 9-10, wherein the application occurs by way of application of a pharmaceutically acceptable carrier and/or by injection, preferably intracutaneous injection of a pharmaceutically acceptable carrier.
- 12. Use according to claim 11, wherein the carrier is selected from the group comprising liposomes, ointments, oils, cremes, emulsions and dispersions.
- 13. Use according to any of claims 10 12, wherein the topical application occurs in a dose range of from 1 ng/ml to 1000 ng/ml.
- 14. Use according to any of claims 10-12, wherein the systemic application occurs in a dose range of from 0.1 µg/kg bodyweight to 100 µg/kg bodyweight.
- 15. Use according to claim 14, wherein the application occurs once to eight times daily.
- 16. Use according to any of claims 9 15, wherein the application occurs before, during and/or after a patient is exposed to UV-radiation.
- 17. Use according to any of claims 9 16, wherein the patient in need is a mammal, preferably a human being.